Do you want to read an article? Please log in or register.
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
Cardiovascular Risk and DiseasesLipid-Lowering Drugs